NMR Measurements of NMR Biomarker GlycA
AssigneeLipoScience, Inc.
InventorsJames D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore
Life of this patent
Estimating the term…
Loading patent…
AssigneeLipoScience, Inc.
InventorsJames D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore
Estimating the term…
Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.
A method of measuring GlycA, comprising:
(canceled)
5-8. (canceled)
10-27. (canceled)
A system, comprising:
36-38. (canceled)
An NMR analyzer comprising:
(canceled)
(canceled)
48-53. (canceled)
Dependencies are inferred from the claim text.